MedTrace Logo

Patiromer With or Without Food for the Treatment of Hyperkalemia

NCT02694744 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2021-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).

Conditions

  • Hyperkalemia

Interventions

DRUG

patiromer

8.4 g/day starting dose, administered orally

Sponsors & Collaborators

  • Relypsa, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director or VP Clinical Development · Relypsa, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-07-31
Completion
2016-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02694744 on ClinicalTrials.gov